drugset

drugset / Trial / NCT07489287

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT07489287 ↗

Phase 1 Recruiting 18 enrolled Roswell Park Cancer Institute Generate Biomedicines · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.

Timeline

Start: 2026-07-15
Primary completion: 2028-01-15
Completion: 2030-01-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GB-5267	Cell therapy	—	Intravenous

Indications